Breaking News

Xencor Receives Janssen R&D Milestone

January 17, 2013

Will use Xtend technology for therapeutic antibody

Xencor, Inc. has received a milestone payment from Janssen R&D for the use of Xencor's Xtend half-life extension technology in a therapeutic antibody. The companies had entered a technology license agreement in 2009. The antibody target and payment amount were not disclosed.
"There has been significant interest in Xtend technology because of the impact it has on the pharmacokinetic properties of antibodies, and we are seeing Xencor technology license agreements with partners translate into promising pipeline programs," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.

Related Contract Manufacturing:

blog comments powered by Disqus
  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research